Eight of the 30 Dow components lost value in 2024. Here's a quick look at each company, to help you determine which dividend ...

But the Dow Jones Industrial Average (DJINDICES ... making it the second most valuable U.S.-based healthcare company behind Eli Lilly. The stock got pummeled in December due to controversy ...

In the latest trading session, Eli Lilly (LLY) closed at $753.98, marking a +1.57% move from the previous day. This move outpaced the S&P 500's daily gain of 0.61%. Meanwhile, the Dow gained 0.3% ...

The Danish drug company said an experimental weight-loss shot helped patients lose over one-fifth of their bodyweight. Novo's U.S. and [Europe-listed s ...

Citi analyst Geoff Meacham maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) today. The company’s shares closed last Friday ...

In a report released today, Terence Flynn from Morgan Stanley reiterated a Buy rating on Eli Lilly & Co (LLY – Research Report), with a ...

In the latest trading session, Eli Lilly (LLY) closed at $753.98, marking a +1.57% move from the previous day. This move outpaced the S&P 500's daily gain of 0.61%. Meanwhile, the Dow gained 0.3%, and ...

US PMI data came in more mixed than expected, to little effect. The Dow Jones Industrial Average (DJIA) churned into a soft backpedal on Friday, testing down around 200 points on a slow trading day.

Tariff threats from the White House are still leaking through, now for February. The Dow Jones Industrial Average (DJIA) absorbed newly-minted President Donald Trump’s last-minute pivot away ...

The Dow Jones rallied on the stock market today. A Donald Trump stock dived while Cathie Wood snapped up a plunging AI stock.

Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has another enormous opportunity that's getting very little attention.